Published in Eur J Endocrinol on April 15, 2013
Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes (2013) 1.17
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology (2016) 1.09
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol (2016) 0.75
Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease. Endocrinol Diabetes Metab Case Rep (2015) 0.75
Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep (2015) 0.75
Metastatic insulinoma managed with radiolabeled somatostatin analog. Case Rep Endocrinol (2013) 0.75
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol (2017) 0.75
Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management. Endocr Connect (2017) 0.75
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol (2006) 4.42
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol (2007) 3.86
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol (2012) 2.92
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet (2006) 2.44
Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35
Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol (2006) 2.34
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 2.22
Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg (2003) 2.20
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol (2002) 2.08
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab (2004) 1.91
ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med (2013) 1.79
New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2008) 1.76
Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol (2006) 1.74
Predicting visual outcome after treatment of pituitary adenomas with optical coherence tomography. Am J Ophthalmol (2008) 1.73
Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab (2007) 1.72
Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab (2014) 1.72
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol (2006) 1.71
Pancreas divisum is not a cause of pancreatitis by itself but acts as a partner of genetic mutations. Am J Gastroenterol (2011) 1.71
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology (2012) 1.68
Metformin-associated vitamin B12 deficiency. Arch Intern Med (2002) 1.67
Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab (2005) 1.64
Reappraisal of central pancreatectomy a 12-year single-center experience. JAMA Surg (2014) 1.62
18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med (2013) 1.61
Streptobacillosis characterised by palmoplantar pustulosis. Lancet Infect Dis (2013) 1.60
Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab (2013) 1.59
Is idiopathic chronic pancreatitis an autoimmune disease? Clin Gastroenterol Hepatol (2005) 1.57
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med (2005) 1.55
Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. Pancreatology (2004) 1.54
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab (2007) 1.53
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery (2005) 1.51
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol (2002) 1.51
Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology (2008) 1.51
Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg (2010) 1.48
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab (2010) 1.46
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer (2011) 1.46
Medullary thyroid carcinoma. Clin Endocrinol (Oxf) (2004) 1.42
Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab (2004) 1.35
Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid (2005) 1.32
Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer (2014) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas (2008) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol (2002) 1.27
Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery (2010) 1.26
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol (2008) 1.22
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med (2005) 1.21
Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol (2006) 1.19
Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res (2008) 1.19
Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep (2013) 1.19
Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab (2004) 1.19
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab (2005) 1.18
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2003) 1.17
Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol (2008) 1.17
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol (2008) 1.15
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.15
Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid (2002) 1.13
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging (2011) 1.13
Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol (2007) 1.12
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab (2012) 1.11
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? Eur J Gastroenterol Hepatol (2010) 1.10
Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? Pancreas (2005) 1.10
Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab (2008) 1.10
Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab (2012) 1.10
Macrocystic pancreatic cystadenoma: The role of EUS and cyst fluid analysis in distinguishing mucinous and serous lesions. Gastrointest Endosc (2004) 1.09
Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. J Am Coll Surg (2005) 1.09
Intraductal papillary mucinous tumors of the pancreas: the preoperative value of cytologic and histopathologic diagnosis. Gastrointest Endosc (2003) 1.08
Pancreaticoduodenectomy with mesentericoportal vein resection for adenocarcinoma of the pancreatic head. World J Surg (2006) 1.08
Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. Eur J Gastroenterol Hepatol (2013) 1.08